Publications by authors named "J Rivera-Nieves"

Background: Tumor necrosis factor (TNF) is a pleiotropic cytokine that plays a critical role in the pathogenesis of immune-mediated diseases including inflammatory bowel disease (IBD). The stability of its mRNA transcript, determined in part by destabilizing sequences in its AAUU repeats (ARE) gene region, is an important regulator of its tissue and systemic levels. A deletion in the ARE region of the gene resulted in IBD and arthritis in mice and pigs, supporting a critical role for the cytokine in human IBD and several human arthritides.

View Article and Find Full Text PDF
Article Synopsis
  • Inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis are chronic conditions affecting the intestines, leading to new treatment options through immunotherapies.
  • Recently developed S1P modulators, such as ozanimod and etrasimod, work by sequestering T cells in lymphoid tissues, reducing their migration to inflamed gut areas, which helps in controlling IBD symptoms.
  • This review highlights the role of the S1P/S1PR signaling pathway in IBD, evaluates the effectiveness and safety of current S1P modulators, and explores future treatment possibilities targeting this pathway.
View Article and Find Full Text PDF

Eighty percent of antibody secreting cells (ASCs) are found in the intestine, where they produce grams of immunoglobulin (Ig) A daily. immunoglobulin A is actively transcytosed into the lumen, where it plays a critical role in modulating the gut microbiota. Although loss of immune tolerance to bacterial antigens is the likely trigger of the dysregulated immune response that characterizes inflammatory bowel disease (IBD), little effort has been placed on understanding the interface between B cells, IgA, and the microbiota during initiation or progression of disease.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD), has emerged as a global disease with an increasing incidence in developing and newly industrialized regions such as South America. This global rise offers the opportunity to explore the differences and similarities in disease presentation and outcomes across different genetic backgrounds and geographic locations. Our study includes 265 IBD patients.

View Article and Find Full Text PDF